linjc16/ctgov huggingface dataset:
Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection

Study Overview
=================
Brief Summary
-----------------
The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.

Detailed Description
-----------------
This is a single-center, observational study. Patients with Acinetobacter baumannii infection in the intensive care unit of Zhongda Hospital were enrolled. We recorded the data of age, ICU admission diagnosis, underlying diseases, APACHE II score and infection site. Body temperature, heart rate, white blood cell counts, procalcitonin, C-reactive protein, SOFA score and the level of CD4+, CD8+, Th1, Th2 and HLA-DR in the blood measured by flow cytometry on the D1, D3 and D7 were also recorded.We can get the results of the change of immune function of critical ill patients after Acinetobacter baumannii infection. After compare the patients who die of survive at 28 day after infection, we can get the results of the relationship between the immune function and the outcome. We also can calculate the effect immune function on prognositic mortality in patients with Acinetobacter baumannii infection.

Official Title
-----------------
Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection

Conditions
-----------------
Acinetobacter Baumannii Infection

Intervention / Treatment
-----------------
* Other: None intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted to ICU Infection with Acinetobacter baumannii Agree to participate the study Exclusion Criteria: Age less than 16 years old or older than 80 years old pregnancy immunosuppression patients which include therapy 0.5mg/kg/day of prednisoneover(equivalent dose of other glucocorticoids) for at least 1 month within recent 3 month Cancer chemotherapy within recent 3 month Receive immunosuppression treatment because of solid organ transplant or Autoimmune diseases allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation. HIV infection

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acinetobacter baumannii infection<br>Critically ill patients infect with Acinetobacter baumannii | Other: None intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28 day mortality |  | 28 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
A baumannii infection, Immunosuppression, prognosis, immune function
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Study Overview
=================
Brief Summary
-----------------
carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a standard treatment for this unusual group of patients who are not usually eligible for clinical trials.

Detailed Description
-----------------
Upon determination of eligibility, patients will be receive: Paclitaxel + Carboplatin + Etoposide

Official Title
-----------------
Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma

Conditions
-----------------
Neuroendocrine Carcinoma

Intervention / Treatment
-----------------
* Drug: Paclitaxel
* Drug: Carboplatin
* Drug: Etoposide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be included in this study, you must meet the following criteria: Metastatic poorly differentiated neuroendocrine carcinoma Unknown primary site Able to perform activities of daily living with minimal assistance Measurable or evaluable disease Adequate bone marrow, liver functions and kidney function No previous treatment with chemotherapy Understand the nature of this study and give written informed consent. Exclusion Criteria: You cannot participate in this study if any of the following apply to you: Age < 18 years Previous malignancy within five years Women pregnant or lactating Recent history of cardiovascular disease Meningeal metastases Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Paclitaxel|nan|
|Drug: Carboplatin|nan|
|Drug: Etoposide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall response |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  |  | 
| Time to progression |  |  | 
| Overall toxicity |  |  |
Study to Evaluate the Safety of Nanoxel M Inj.

Study Overview
=================
Brief Summary
-----------------
Study to evaluate the safety of Nanoxel M inj. administration in patients.

Detailed Description
-----------------
This is a multi-center, prospective observational study to observe the incidence of adverse events under actual clinical settings to test the safety of Nanoxel-M inj. administration in patients with breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, head & neck cancer, gastric cancer or esophageal cancer.

Official Title
-----------------
An Observational Study to Evaluate the Safety of Nanoxel M (Docetaxel-PM) Inj.

Conditions
-----------------
Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults ≥18 years old Patients who have signed written consent form prior to participating in the clinical trial Patients who are assessed as adequate to administer Nanoxel M injection. Exclusion Criteria: 1) Patients who have shown severe hypersensitivity to Docetaxel and concomitant drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of Nanoxel M inj. | The incidence of Treatment-Emergent Adverse Event | through study completion, an average of 6cycles(each cycle is 3weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Observational Study, Safety, Nanoxel M, Docetaxel
Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to explore ways to improve and simplify control of blood pressure in patients with SAH or ICH. This research will be done by comparing tow different medications that are routinely used to help control blood pressure. None of the medications used in this study nor any procedures performed are experimental.

Conditions
-----------------
Subarachnoid Hemorrhage, Intracerebral Hemorrhage

Intervention / Treatment
-----------------
* Drug: Nicardipine and Nipride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-70 years old (inclusive) Admission to NSICU with a diagnosis of SAH or ICH Exclusion Criteria: Patients who are admitted >48 hours after SAH or ICH Readmission or second SAH Readmission or second ICH Large (immediately life threatening) associated intraparenchymal or intraventricular hemorrhage Women who are pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nicardipine and Nipride|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients with SAH or ICH
Corneal Asphericity Adjustment (Q Adjustment) in Myopic and Hyperopic Patients Undergoing Refractive Correction With Excimer Laser

Study Overview
=================
Brief Summary
-----------------
To study the postoperative results in myopic and hyperopic eyes treated with two different laser ablation algorithms (STD and F-CAT), both FDA approved.

Conditions
-----------------
Myopia, Hyperopia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Myopic and hyperopic eyes eligible for LASIK or PRK refractive correction Central corneal thickness more than 500 micrometers Exclusion Criteria: Topographies of less than 55% of successful total sampled area and eyes exhibiting asphericity variations, in either the horizontal or the vertical axis, greater than 0.2 Corneal scarring Cataract surgery Corneal ulceration Topographical abnormalities
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laser ablation algorithms, Excimer laser, Refractive correction, Corneal Asphericity Adjustment
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)

Study Overview
=================
Brief Summary
-----------------
This observational study will examine the safety and efficacy profile of Elonva (corifollitropin alfa) when administered in Korean women undergoing controlled ovarian stimulation (COS) in combination with a gonadotropin-releasing hormone (GnRH) antagonist for the development of multiple follicles in an assisted reproductive technology (ART) program.

Official Title
-----------------
Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of ELONVA in Usual Practice

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Drug: corifollitropin alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Women with an indication for COS prior to in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) who meet the criteria as mentioned in the current Korean ELONVA local label Exclusion Criteria: Hypersensitivity to the active substance or to any of the excipients Tumors of the ovary, breast, uterus, pituitary or hypothalamus Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. Primary ovarian failure Ovarian cysts or enlarged ovaries A history of OHSS A previous COS cycle that resulted in more than 30 follicles ≥ 11 mm measured by ultrasound examination Basal antral follicle count > 20 Fibroid tumors of the uterus incompatible with pregnancy Malformations of the reproductive organs incompatible with pregnancy Pregnancy Polycystic ovarian syndrome
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Enrolled Participants<br>Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program. | Drug: corifollitropin alfa<br>* 100 or 150 microgram single subcutaneous injection<br>* Other names: Elonva;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Oocytes Retrieved |  | At time of oocyte retrieval (up 3 days from human chorionic gonadotropin [hCG] injection) | 
| Number of Participants who Experience Ovarian Hyperstimulation Syndrome (OHSS) |  | During treatment and up to 30 days after cessation of treatment | 
| Number of Participants who report an serious adverse event (SAE) |  | During treatment and up to 30 days after cessation of treatment | 
| Number of Participants who report an adverse event (AE) |  | During treatment and up to 30 days after cessation of treatment |
Coronary Disease and the Effect of High-intensity Interval Training

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate if systematic, high intensity, interval-based aerobic exercise training results in regression of lipid content of atherosclerotic coronary artery plaques, and in reduction of plaque burden in patients with stable coronary heart disease. Composition and morphologic characteristics of plaques will be studied by intra-coronary near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS) in patients undergoing percutaneous coronary intervention.

Official Title
-----------------
Physical Activity and Lipid Content of Coronary Artery Atheromatous Plaques: a Randomised Trial Using Novel Intracoronary Imaging Techniques

Conditions
-----------------
Coronary Disease

Intervention / Treatment
-----------------
* Behavioral: high intensity interval-based aerobic exercise
* Other: Usual care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stable coronary artery disease will undergo cardiac catheterization will be treated with percutaneous coronary intervention (PCI) signed written informed consent able to execute the intervention Exclusion Criteria: earlier bypass surgery known inflammatory disease other than atherosclerosis planned surgery within 4 months included in another randomized controlled study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: interval training<br>high intensity interval-based aerobic exercise | Behavioral: high intensity interval-based aerobic exercise<br>* Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.<br>Other: Usual care<br> <br> |
| Other: controls<br>usual care | Other: Usual care<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lipid content of atherosclerotic coronary artery plaques | Lipid core burden index (LCBI) measured by intracoronary near-infrared spectroscopy | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary Angiography, Exercise
Role of Interleukin-6 in Exercise

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to understand the role of interleukin-6 during physical activity in patients with type 2 diabetes.

Official Title
-----------------
A Lifestyle Intervention Study Investigating the Role of Interleukin-6 in the Beneficial Effect of Exercise on Beta-cell Function in Obese People and Patients With Type 2 Diabetes

Conditions
-----------------
Diabetes Mellitus, Type 2, Obesity

Intervention / Treatment
-----------------
* Behavioral: Sport
* Drug: Tocilizumab
* Drug: Sitagliptin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Obesity group: BMI 30-40 kg/m2, fasting plasma glucose <6.4 mmol/l. Diabetes group: Type 2 diabetes according to American Diabetes Association criteria Exclusion criteria: Anti-diabetic drug other than metformin Diabetes duration of more than 5 years Inflammatory diseases Current infection Liver disease (transaminases >2x upper normal range) kidney disease (creatinine >1.5 mg/dl for men and 1.4 mg/dl for women) pregnancy or breast-feeding, women of child bearing potential not using an acceptable form of contraception immunosuppressive disease corticosteroid use regular non-steroidal antinflammatory drug usage history of carcinoma history of tuberculosis anemia, bleeding disorders obstructive pulmonary disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Tocilizumab<br>Infusion of Tocilizumab and sport intervention | Behavioral: Sport<br> <br> Drug: Tocilizumab<br> <br> |
| Active Comparator: Sitagliptin<br>Intake of Sitagliptin and sport intervention | Behavioral: Sport<br> <br> Drug: Sitagliptin<br> <br> |
| Placebo Comparator: Placebo<br>Intake of placebo and sport intervention | Behavioral: Sport<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucagon like peptide- 1 (GLP-1) |  | Change in GLP-1 secretion compared to baseline |
Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Study Overview
=================
Brief Summary
-----------------
This study is a randomized controlled trial (RCT) comparing adjuvanted influenza vaccine (AV) to unadjuvanted inactivated influenza vaccine (IIV). Children in Hutterite colonies in Alberta and Saskatchewan will receive AV or IIV. The goal of this study is to determine whether the AV vaccine, can provide increased community-wide protection.

Official Title
-----------------
A Randomized Controlled Trial of Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: Fluad
* Biological: Fluzone


Participation Criteria
=================
Eligibility Criteria
-----------------
Group A: Receive Intervention Inclusion Criteria: Healthy children aged 6 months to 72 months Exclusion Criteria: Anaphylactic reaction to a previous dose of influenza vaccine or to any of its components Known Immunoglobulin E (IgE)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock Guillain- Barré syndrome within eight weeks of a previous influenza vaccine Use of aspirin or salicylate- containing products within 30 days before enrollment Group B: Inclusion Criteria: Household members of children in Group A Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 72 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adjuvanted Influenza Vaccine<br>Fluad | Biological: Fluad<br> <br> |
| Active Comparator: Quadrivalent Influenza Vaccine<br>Fluzone | Biological: Fluzone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laboratory-confirmed influenza infection |  | Up to 3 years |
Relations Between Residual Renal Function and Oxidative and Carbonyl Stress in Peritoneal Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
Residual renal function is reported to contribute to the survival and cardiovascular disease of peritoneal dialysis patients. Oxidative and carbonyl stress are increased in peritoneal dialysis patients and are associated with cardiovascular risk. The aim of this study was to determine the relations between residual renal function and oxidative and carbonyl stress in peritoneal dialysis patients.

Official Title
-----------------
Relations Between Residual Renal Function and Oxidative and Carbonyl Stress in Peritoneal Dialysis Patients

Conditions
-----------------
Chronic Renal Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic renal failure on peritoneal dialysis Exclusion Criteria: malignancy, peritonitis

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>with residual renal function | |
| B<br>without residual renal function | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
residual renal function, oxidative stress, carbonyl stress, peritoneal dialysis